CD274 and cholangiocarcinoma: Indeed, a recent study suggests that tumor-associated macrophages are the primary source of PD-L1 in cholangiocarcinoma, and targeting myeloid cells sensitizes cholangiocarcinoma to anti-PD1 therapy (Loeuillard et al., 2020).